
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. demonstrated substantial financial growth, with revenue from soft tissue repair products reaching $22.7 million, reflecting a 28% year-over-year increase primarily fueled by rising demand for CellerateRX Surgical Activated Collagen. Additionally, the company's bone fusion products generated $3.1 million in revenue, marking a 25% year-over-year growth, indicating strong performance across multiple product lines. The ongoing strategy to expand distribution partnerships and penetrate healthcare facilities positions Sanara MedTech for continued revenue growth in the future.
Bears say
Sanara MedTech faces several significant risks that contribute to a negative outlook on its stock, primarily centered around lower-than-projected revenue growth from its product portfolio. The company may struggle to secure additional customers, which could hinder its market expansion and revenue potential. Furthermore, the inability to successfully launch new products or services poses a threat to its competitive positioning in the medical technology sector, while potential dilution risks could adversely affect shareholder value.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares